Download PDF
Thromb Haemost 2010; 103(06): 1128-1135
DOI: 10.1160/TH09-11-0799
Clinical Focus
Schattauer GmbH

Platelet function testing and risk of bleeding complications

José Luis Ferreiro
1   University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA
,
Dirk Sibbing
2   Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Technische Universität München, München, Germany
,
Dominick J. Angiolillo
1   University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA
› Author Affiliations
Further Information

Publication History

Received: 25 November 2009

Accepted after minor revision: 19 January 2010

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

Antiplatelet therapy has a key role in preventing atherothrombotic events in patients with coronary artery disease, particularly in those undergoing revascularisation procedures. However, this may occur at the expense of an increase risk of bleeding. Therefore, the balance between thrombotic and bleeding events is critical in order to achieve optimal outcomes. Since there is a broad variability in individual response profiles to antiplatelet therapy, these outcomes (thrombosis vs. bleeding) may depend on the level of platelet inhibition achieved in a given subject. Platelet function assays have emerged as a useful tool for its potential to determine patients at a higher risk of ischaemic and bleeding complications. The present manuscript will review the available evidence associating platelet function testing with adverse clinical outcomes, in particular bleeding, and their potential applications in lieu of novel and more potent antithrombotic agents that will be introduced into clinical practice in the near future.

Keywords

Platelet pharmacology - antiplatelet agents - bleeding
 

  • References

  • 1 Anderson JL, Adams CD, Antman EM. et al ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50: e1-e157.
    CrossrefPubMedGoogle Scholar
  • 2 King SB, 3rd Smith Jr SC, Hirshfeld Jr JW. et al. 2007 focused update of the ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
    CrossrefPubMedGoogle Scholar
  • 3 Faxon DP, Freedman JE. Facts and controversies of aspirin and clopidogrel therapy. Am Heart J 2009; 157: 412-422.
    CrossrefPubMedGoogle Scholar
  • 4 Eikelboom JW, Mehta SR, Anand SS. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
    CrossrefPubMedGoogle Scholar
  • 5 Ndrepepa G, Berger PB, Mehilli J. et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697.
    CrossrefPubMedGoogle Scholar
  • 6 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
    CrossrefPubMedGoogle Scholar
  • 7 Ferreiro JL, Angiolillo DJ. Clopidogrel Response Variability: Current Status and Future Directions. Thromb Haemost 2009; 102: 7-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e489-493.
    CrossrefPubMedGoogle Scholar
  • 9 Harrison P. Platelet function analysis. Blood Rev 2005; 19: 111-123.
    CrossrefPubMedGoogle Scholar
  • 10 Williams CD, Cherala G, Serebruany V. Application of platelet function testing to bedsite. Thromb Haemost 2010; 103: 29-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Nikolsky E, Mehran R, Dangas G. et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-1945.
    CrossrefPubMedGoogle Scholar
  • 12 Subherwal S, Bach RG, Chen AY. et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009; 119: 1873-1882.
    CrossrefPubMedGoogle Scholar
  • 13 Pocock SJ, Mehran R, Clayton TC. et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2010; 121: 43-51.
    CrossrefPubMedGoogle Scholar
  • 14 Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 2008; 28: s25-32.
    CrossrefPubMedGoogle Scholar
  • 15 Antithrombotic Trialists’ Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
    CrossrefPubMedGoogle Scholar
  • 16 Serebruany VL, Steinhubl SR, Berger PB. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95: 1218-1222.
    CrossrefPubMedGoogle Scholar
  • 17 Steinhubl SR, Bhatt DL, Brennan DM. et al CHARISMA Investigators.. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009; 150: 379-386.
    CrossrefPubMedGoogle Scholar
  • 18 Topol EJ, Easton D, Harrington RA. et al Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators.. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108: 399-406.
    CrossrefPubMedGoogle Scholar
  • 19 Yusuf S, Zhao F, Mehta SR. et al Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
    CrossrefPubMedGoogle Scholar
  • 20 Peters RJ, Mehta SR, Fox KA. et al Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators.. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-1687.
    CrossrefPubMedGoogle Scholar
  • 21 Bhatt DL, Fox KA, Hacke W. et al CHARISMA Investigators.. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
    CrossrefPubMedGoogle Scholar
  • 22 Wiviott SD, Trenk D, Frelinger AL. et al. PRINCIPLE-TIMI 44 Investigators.. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
    CrossrefPubMedGoogle Scholar
  • 23 Wiviott SD, Braunwald E, McCabe CH. et al TRITON-TIMI 38 Investigators.. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    CrossrefPubMedGoogle Scholar
  • 24 Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.
    CrossrefPubMedGoogle Scholar
  • 25 Wallentin L, Becker RC, Budaj A. et al. for the PLATO Investigators.. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1-13.
    CrossrefPubMedGoogle Scholar
  • 26 Wong PC, Crain EJ, Watson CA. et al. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 2009; 101: 108-115.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Poston R, Gu J, Manchio J. et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005; 27: 584-591.
    CrossrefPubMedGoogle Scholar
  • 28 Spiess BD, Gillies BS, Chandler W. et al. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 09: 168-173.
    CrossrefPubMedGoogle Scholar
  • 29 Chen L, Bracey AW, Radovancevic R. et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004; 128: 425-431.
    CrossrefPubMedGoogle Scholar
  • 30 Rahe-Meyer N, Winterhalter M, Boden A. et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009; 53: 168-175.
    CrossrefPubMedGoogle Scholar
  • 31 Cuisset T, Cayla G, Frere C. et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 05: 325-329.
    PubMedGoogle Scholar
  • 32 Sibbing D, Schulz S, Braun S. et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 08: 250-256.
    CrossrefPubMedGoogle Scholar
  • 33 Serebruany V, Rao SV, Silva MA. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31: 227-235.
    CrossrefPubMedGoogle Scholar
  • 34 Michelson AD, Frelinger AL, Braunwald E. et al for the TRITON–TIMI 38 Investigators.. Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 Trial. Eur Heart J 2009; 30: 1753-1763.
    CrossrefPubMedGoogle Scholar
  • 35 Angiolillo DJ, Bhatt DL, Gurbel PA. et al. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009; 103 (Suppl): 40A-51A.
    CrossrefPubMedGoogle Scholar
  • 36 Breet NJ, Bouman HJ, van Werkum JW. et al. First prospective comparison between platelet function tests in prediction of clinical outcome in 1100 patients undergoing coronary stent placement: Do point-of-care platelet function assays predict clinical outcomes in clopidogrel pretreated patients undergoing elective PCI (POPular Study). Circulation 2009; 120: 2153 [Abstract].
    PubMedGoogle Scholar
  • 37 Angiolillo DJ, Capranzano P, Desai B. et al. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 2009; 124: 318-322.
    CrossrefPubMedGoogle Scholar
  • 38 Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: hype or hope?. J Am Coll Cardiol 2006; 48: 1751-1754.
    CrossrefPubMedGoogle Scholar
  • 39 Angiolillo DJ, Bernardo E, Palazuelos J. et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 2008; 99: 161-168.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Cuisset T, Frere C, Quilici J. et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders. J Am Coll Cardiol Interv 2008; 01: 649-653.
    CrossrefPubMedGoogle Scholar
  • 41 Bonello L, Camoin-Jau L, Armero S. et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
    CrossrefPubMedGoogle Scholar
  • 42 Valgimigli M, Campo G, de Cesare N. et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. Cardiovasc Drugs Ther 2008; 22: 313-320.
    CrossrefPubMedGoogle Scholar
  • 43 Price MJ, Berger PB, Angiolillo DJ. et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009; 157: 818-824.
    CrossrefPubMedGoogle Scholar
  • 44 Marín F, González-Conejero R, Capranzano P. et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 2009; 54: 1041-1057.
    CrossrefPubMedGoogle Scholar
  • 45 Simon T, Verstuyft C, Mary-Krause M. et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators.. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
    CrossrefPubMedGoogle Scholar
  • 46 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
    CrossrefPubMedGoogle Scholar
  • 47 Sibbing D, Stegherr J, Latz W. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
    PubMedGoogle Scholar
  • 48 Sim SC, Risinger C, Dahl ML. et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
    CrossrefPubMedGoogle Scholar
  • 49 Sibbing D, Koch W, Gebhardt D. et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events and stent thrombosis in clopidogrel treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
    CrossrefPubMedGoogle Scholar